Can Trelegy (fluticasone furoate, umeclidinium, and vilanterol) be taken after coronary artery bypass grafting (CABG) or open heart surgery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Trelegy can generally be taken after coronary artery bypass grafting (CABG) or open heart surgery, but it's essential to consult with your cardiologist and pulmonologist before resuming or starting this medication. Trelegy is an inhaled combination medication containing fluticasone (a corticosteroid), umeclidinium (an anticholinergic), and vilanterol (a long-acting beta-agonist) used to treat COPD and asthma. After heart surgery, your healthcare team will need to evaluate your respiratory function, cardiovascular status, and potential drug interactions with your post-surgical medications.

Key Considerations

  • Typically, if you were using Trelegy before surgery, you can resume it once your condition is stable and your doctor approves, usually within days to weeks after surgery.
  • The timing depends on your recovery progress, lung function, and overall health status.
  • Trelegy helps manage respiratory conditions by reducing inflammation, relaxing airway muscles, and improving breathing, which may be beneficial during recovery, but the beta-agonist component could potentially affect heart rate and blood pressure, requiring careful monitoring after cardiac surgery 1.

Post-Surgical Care

  • Postoperative care after open heart surgery often involves managing respiratory complications, as noted in a study on open-lung ventilation strategies 2.
  • Another study highlighted the importance of patient education on congestive heart failure self-care after open heart surgery to prevent fluid volume overload and reduce CHF-related concerns 1.
  • While these studies do not directly address the use of Trelegy, they emphasize the need for careful management of respiratory and cardiovascular health post-surgery.

Medication Management

  • The decision to resume or start Trelegy should be based on individual patient assessment, considering the potential benefits of the medication in managing respiratory conditions against the potential risks, especially the impact of the beta-agonist component on heart rate and blood pressure.
  • As there is no direct evidence from the provided studies on the use of Trelegy after CABG or open heart surgery, the approach should be cautious and personalized, with close monitoring by healthcare professionals 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.